Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 16;8(44):76974-76986.
doi: 10.18632/oncotarget.20293. eCollection 2017 Sep 29.

The Prognostic Significance of Combined Androgen Receptor, E-Cadherin, Ki67 and CK5/6 Expression in Patients With Triple Negative Breast Cancer

Affiliations
Free PMC article

The Prognostic Significance of Combined Androgen Receptor, E-Cadherin, Ki67 and CK5/6 Expression in Patients With Triple Negative Breast Cancer

Barbara Adamo et al. Oncotarget. .
Free PMC article

Erratum in

Abstract

Background: Triple Negative Breast Cancer (TNBC) represents a heterogeneous group of tumors with poor prognosis owing to aggressive tumor biology and lack of targeted therapies. No clear prognostic biomarkers have been identified to date for this subgroup.

Materials and methods: In this retrospective study we evaluated the prognostic role of 4 different molecular determinants, including androgen receptor (AR), E-cadherin (CDH1), Ki67 index, and basal cytokeratins (CKs) 5/6, in a cohort of 99 patients with TNBC. All patients received neo/adjuvant chemotherapy (mostly anthracycline/taxane-based). Immunohistochemistry (IHC) was performed in formalin-fixed paraffin-embedded primary tumor samples. CDH1 expression was considered positive as ≥ 30% of the membrane cells staining. AR positivity was defined as > 10% of positive tumor cells. High Ki67 was defined as ≥20% positive tumor cells. CK5/6 expression was judged positive if the score was ≥1.

Results: The absence of AR expression was significantly associated with highly undifferentiated tumors. Univariate analyses showed that lack of expression of CDH1, tumor size and nodal status were significantly correlated with worse RFS and OS (p< 0.05). AR expression and low Ki67 showed a trend towards better RFS and OS. Patients with absent CK5/6 expression in univariate and multivariate analyses had poorer RFS (p=0.02 and p=0.002, respectively) and OS (p=0.05 and p=0.02, respectively). Multivariate analysis showed an independent association between CDH1 expression and better RFS and OS (p< 0.05) beyond tumor size, nodal status, and grade. The Kaplan-Meier curves showed that patients with AR and CDH1 negative expression and high Ki-67 levels have a significant correlation with poor outcome.

Conclusions: Our study supports the use of IHC expression of AR, CDH1, Ki67, and CK5/6 as prognostic markers in TNBCs and suggests a link between their expression and prognosis and may help to stratify TNBC patients in different prognostic classes.

Keywords: CK5/6; Ki67; androgen receptor; e-cadherin; triple negative breast cancer.

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest declared.

Figures

Figure 1
Figure 1. E-Cadherin, Ki67, AR, and CK5/6 expression by IHC
(A, B) E-cadherin negative/positive staining; (C, D) Ki-67 level < or ≥ 20%; (E, F) negative/positive AR staining; (G, H) negative/positive CK5/6 staininig.
Figure 2
Figure 2. Estimated RFS and OS curves for CDH1, AR and Ki67 expression

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34. - PubMed
    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48. - PubMed
    1. Adamo V, Ricciardi GR, De Placido S, Colucci G, Conte P, Giuffrida D, Gebbia N, Masci G, Cognetti F, Dondi D, Venturini M. Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer. 2012;48:642–7. - PubMed
    1. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist. 2011;16:71–8. - PubMed
    1. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123–33. - PMC - PubMed
Feedback